2023
DOI: 10.1101/2023.12.18.572273
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

SGLT2 inhibitors attenuate endothelial to mesenchymal transition and cardiac fibroblast activation

Kevin Schmidt,
Arne Schmidt,
Sonja Groß
et al.

Abstract: Beneficial effects of sodium glucose co-transporter 2 inhibitors (SGLT2is) in cardiovascular diseases have been extensively reported leading to the inclusion of these drugs in the treatment guidelines for heart failure. However, molecular actions especially on non-myocyte cells remain uncertain. We observed dose-dependent inhibitory effects of two SGLT2is, dapagliflozin (DAPA) and empagliflozin (EMPA), on inflammatory signaling in human umbilical vein endothelial cells (HUVECs). Proteomics analyses and subsequ… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 68 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?